Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
NCT01927406 · Stanford University · PHASE4 · withdrawn · last registry update 2018-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding source unavailable” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-23Results posted on the registry: University of Texas Southwestern Medical Center, Dexmedetomidine + Glycopyrrolate (NCT02524145)
- 2018-12-19Phase 3 first posted: Hospices Civils de Lyon, Landiolol + Placebo (NCT03779178)
- 2018-12-19Phase 3 first posted: AbbVie, ABBV-951 (NCT03781167)
- 2018-04-17Phase 3 first posted: Actavis Inc., Nepafenac 0.3% Oph Susp + Placebos (NCT03499873)
- 2018-02-01Phase 3 first posted: SWOG Cancer Research Network, Carvedilol (NCT03418961)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision